Journavx is designed to eliminate the risks of addiction and overdose associated with medications like Vicodin and OxyContin.

Shares of Vertex Pharmaceuticals Inc. surged ahead of Friday’s market open after the Food and Drug Administration approved ...

The U.S. Food and Drug Administration has approved Vertex Pharmaceuticals' drug to treat acute pain, the health regulator ...

Shares of Vertex Pharmaceuticals rose after Journavx, the company’s oral non-opioid pain medication, received Food and Drug ...

The bottom line is few companies can match its combination of established leadership in rare diseases and realistic pathways ...

Vertex Pharmaceuticals (VRTX – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Terence ...

Barclays analyst Gena Wang raised the firm’s price target on Vertex Pharmaceuticals (VRTX) to $435 from $418 and keeps an Equal Weight rating ...

Vertex Pharmaceuticals won FDA approval for its non-opioid painkiller Journavx. Vertex stock jumped in late trading.

Fintel reports that on January 30, 2025, Wells Fargo downgraded their outlook for Vertex Pharmaceuticals (NasdaqGS:VRTX) from ...

Vertex has gained the FDA's approval for its non-addictive pain med Journavx, which becomes the first significant innovation ...

Despite high demand for an option like Journavx, doctors fear the drug’s price could be a major hangup for insurers, ...